H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on TPST stock, giving a Hold rating on April 25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Hold rating due to a combination of factors surrounding Tempest Therapeutics’ lead asset, amezalpat. The data presented at the AACR conference highlighted the promising anti-tumor response of amezalpat, particularly in its role as a competitive antagonist of PPARα, which is being evaluated in a Phase 2 study for metastatic HCC. Despite the encouraging clinical benefits observed when amezalpat is added to the current standard of care, Pantginis remains cautious as the company is undergoing a strategic reorganization.
While the mechanistic findings of amezalpat, such as its impact on immune cells and cytokine levels, are promising, Pantginis is likely waiting for further updates on Tempest’s strategic plans and additional clinical data before considering a more favorable rating. The Hold rating reflects a balanced view, acknowledging the potential of amezalpat while also considering the uncertainties that come with Tempest’s current phase of development.
Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Actinium Pharmaceuticals. According to TipRanks, Pantginis has an average return of -19.8% and a 22.78% success rate on recommended stocks.